Loading
Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it.
David Gershenson is a gynaecologic oncologist at MD Anderson Cancer Center whose work established low-grade serous carcinoma of the ovary as a separate, relatively chemotherapy-resistant disease. He was first author of the 2017 Journal of Clinical Oncology study of hormonal maintenance therapy after primary treatment and of the 2022 Lancet report of GOG 281/LOGS, in which trametinib lengthened progression-free survival compared with standard-of-care options in recurrent low-grade serous carcinoma. He has also led studies of rare ovarian germ cell and sex cord-stromal tumours.
| Title | Journal | Year |
|---|---|---|
| GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer | The Lancet | 2022 |
| Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum | Journal of Clinical Oncology | 2017 |
MEK inhibition is a standard option for recurrent low-grade serous ovarian cancer, and the trial validated the MAPK pathway as the disease's therapeutic target, now extended by avutometinib-defactinib.
Letrozole maintenance after first-line therapy is now common practice and guideline-supported for low-grade serous ovarian cancer, and the randomised NRG-GY019 trial is testing letrozole alone.
Shares Low-grade serous ovarian cancer, Ovarian cancer and the tags ovarian, gynaecological, trialist.
Shares MD Anderson Cancer Center, Ovarian cancer and the tags gynaecological, trialist.
Shares Ovarian cancer and the tags ovarian, trialist.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.
Shares Ovarian cancer and the tags ovarian, trialist.
Shares the tags gynaecological, trialist.